Market Segmentation:
- By Treatment Type
- Dietary Management
- Enzyme Replacement Therapy
- Gene Therapy
- Liver Transplantation
- Others (Supportive Care, Symptomatic Treatment)
- By Route of Administration
- Oral
- Intravenous
- Others (Intramuscular, Subcutaneous)
- By Age Group
- Neonates
- Infants
- Children
- Adults
- By Distribution Channel
- Hospital Pharmacies
- Specialty Pharmacies
- Online Pharmacies
- Others (Retail Pharmacies, Mail-order Pharmacies)
- By End-User
- Hospitals
- Clinics
- Homecare Settings
- Others (Research Institutes, Academic Centers)
- By Dosage Form
- Tablets
- Capsules
- Injections
- Oral Solutions
- Others (Powder, Granules)
- By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the Argininosuccinic Aciduria industry is estimated to be USD 120 million.
Increasing prevalence of inherited metabolic disorders, rising awareness and early diagnosis, advancements in diagnostic techniques, growing demand for effective treatments, development of innovative therapies, expansion of newborn screening programs, and improving healthcare infrastructure in emerging markets.
High treatment costs, lack of approved therapies, challenges in disease management, limited availability of specialized care, low disease awareness in certain regions, and regulatory hurdles for orphan drug development.
The leading component segment in the Argininosuccinic Aciduria Market is the Dietary Management segment, which involves protein restriction and amino acid supplementation.
The major players operating in the Argininosuccinic Aciduria Market include Horizon Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Homology Medicines, Codiak BioSciences, Audentes Therapeutics (acquired by Astellas Pharma), Modalis Therapeutics, and Lucane Biosciences.
The global Argininosuccinic Aciduria Market is expected to reach US$ 266.7 Million by 2031, with a growth rate of 10.5% during the forecast period.
Increasing prevalence of inherited metabolic disorders, rising awareness and early diagnosis, advancements in diagnostic techniques, growing demand for effective treatments, development of innovative therapies, expansion of newborn screening programs, and improving healthcare infrastructure in emerging markets.